urothelial carcinoma (UC), and compared survival to that in patients with pure UC of the bladder. METHODS: We identified 35 patients with plasmacytoid UC and 857 with pure UC who were treated with RC between 1980 and 2007. All pathologic specimens were re-reviewed by a single GU pathologist. Patients were matched 1:2 by age, gender, ECOG perfor- mance status, pathological tumor stage and nodal status to patients with UC. Survival was estimated using the Kaplan-Meier method and compared with the log rank test. RESULTS: Patients with plasmacytoid UC were more likely to have extravesical disease (¡ÝpT3) (86% versus 42%, p<0.0001) and positive margins (31% versus 2.1%, p<0.0001), than patients with pure UC. They were also more likely to experience a local recurrence (RR 2.7, p¼0.0004), with a 46% 10-year recurrence free survival compared to 79% in patients with pure UC. Patients with plasmacytoid UC dis- played a trend toward decreased 10-year overall (15% versus 30%, p¼0.07) and cancer specific survival (28% versus 51%, p¼0.05). When patients with plasmacytoid UC were matched to those with pure UC, there were no significant differences in 10-year overall, cancer specific, local or distant recurrence free survival. CONCLUSIONS: Plasmacytoid UC is associated with a high rate of locally advanced disease and positive margins at RC, as well as increased local recurrence rates. Further research is necessary to delineate adjuvant or neoadjuvant treatment strategies to improve local cancer control this rare subtype of UC. Source of Funding: None MP72-12 OUTCOMES OF RADICAL CYSTECTOMY IN POTENTIAL CANDIDATES FOR BLADDER PRESERVATION THERAPY Eugene Pietzak, III*, Matthew Sterling, S. Bruce Malkowicz, Thomas Guzzo, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Bladder Preservation Therapy (BPT) in urothelial-type bladder cancer (UBC) is often compared to Radical Cystectomy (RC). However, BPT patients are subject to stringent selection criteria which limit comparisons. Our objective was to analyze the outcomes of RC in patients who otherwise met criteria for BPT. METHODS: We identified consecutive patients with clinical stage cT2N0M0 UBC who underwent RC with curative intent at our academic center. Patients without carcinoma in-situ (CIS), hydro- nephrosis, multifocality, or mixed histology were classified as BPT-eligible. Patients with 1 contraindications were considered BPT-ineligible. Clinicopathologic characteristics and survival outcomes for BPT-eligible were compared to ineligible patients. RESULTS: 275 patients had cT2N0M0 UBC, of which 157 (57.1%) were BPT-ineligible (CIS¼54; hydro¼77; multifocality¼29; mixed histology¼55; 2 contraindications¼51). BPT-eligible and ineligible patients did not statistically differ with regards to age, gender, race, or neoadjuvant chemotherapy. Of the BPT-eligible pa- tients, 24.1% had occult positive lymph nodes and 36.4% had pT3/ pT4 tumors at RC. On multivariable analysis, mixed histology (OR¼3.18[95%CI:1.18-8.56]) and progression from non-invasive dis- ease to cT2 (OR¼4.81[95%CI:1.67-13.85]) were independently associated with upstaging. Two-year overall survival was higher in BPT-eligible patients (76.7% v. 57.1% p¼0.003; HR¼0.48[95% CI:0.3-0.78]). BPT-eligible patients also had better cancer-specific mortality on competing risk analysis (Sub-HR¼0.46[95%CI¼0.29- 0.72] p¼0.001). CONCLUSIONS: Substantial clinical-pathologic stage discrep- ancies occurred even in patients seemingly ideal for BPT, which may provide insight into BPT failures. Furthermore, substantial survival discrepancies occurred between BPT-eligible and BPT-ineligible patients despite being the same clinical stage. In the absence of randomized trials, comparisons between RC and BPT must factor in selection bias. Source of Funding: None MP72-13 OUTCOMES OF RADICAL CYSTECTOMY IN PATIENTS WITH BLADDER CANCER AND UNCONTROLLED DIABETES: A POPULATION-BASED STUDY Izak Faiena*, Viktor Dombrovskiy, Raymond Sultan, Amirali Salmasi, Eric Singer, Robert Weiss, New Brunswick, NJ INTRODUCTION AND OBJECTIVES: Radical cystectomy is often performed in patients with multiple comorbidities, including dia- betes. We evaluated complications, mortality, hospital length of stay (LOS) and cost in this cohort. METHODS: Patients with bladder cancer who underwent radical cystectomy, including those with diabetes, were selected from the National Inpatient Sample 2001-2012 using the appropriate ICD-9- CM codes. Chi-square and Wilcoxon rank-sum tests, multivariable lo- gistic regression and generalized linear models with adjustment for patient demographic and hospital characteristics and comorbidities were used for statistics. LOS and cost were presented as median with interquartile range (IQR). RESULTS: In the study population, 989 patients had uncon- trolled diabetes (UD), 15,693 controlled diabetes (CD), and 73,603 no diabetes (ND). Postoperative complications were significantly more common in UD (73%) compared to CD (51%) and ND (52%); P<0.0001. In the multivariable analysis, UD compared to CD were more likely to have any complication (OR¼2.3; 95%CI 2.01-2.71), including infectious (OR¼2.6; 95% CI 2.29-3.07) and respiratory (OR¼1.9; 95%CI 1.61-2.28) complications, bleeding (OR¼1.2; 95% CI 1.06-1.48), sepsis (OR¼2.6; 95% CI 2.18-3.22), surgical site infection Vol. 193, No. 4S, Supplement, Monday, May 18, 2015 THE JOURNAL OF UROLOGY â e925